4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million
4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million 4D Molecular Therapeutic
4D Molecular Therapeutics Q3 2026 net loss widens 37% to $78.06 million 4D Molecular Therapeutic